Rhumatologie

Impact of terminating reimbursement of symptomatic slow-acting drugs in osteoarthritis in France

Impact of terminating reimbursement of symptomatic slow-acting drugs in osteoarthritis in France on volume and cost of drug deliveries, assessed with administrative databases

With osteoarthritis (OA)

As one of the leading causes of disability in adults worldwide, its toll on patients and its economic burden for payers are substantial. The issue of change in OA management with the evolution of reimbursement schemes needs to be addressed.

Objective

To assess the impact of terminating the reimbursement of symptomatic slow-acting drugs in OA (SYSADOAs) in France in terms of volume and cost, from a healthcare payer perspective.

Major conclusions

Our results did not show a measurable impact of terminating SYSADOA reimbursement on the delivery of NSAIDs and analgesics or on hospitalizations. However, neither do they allow for concluding that terminating SYSADOA reimbursement did not generate an increase in deliveries of non-reimbursed drugs, with their associated potential risks for public health.

     

    Comment évaluer l’impact du déremboursement d’une classe thérapeutique sur les consommations de soins et les coûts pour l’Assurance Maladie à partir des données du SNDS: une étude réalisée par RCTs en collaboration avec l’INSERM et les laboratoire Genévrier.

    https://doi.org/10.1016/j.semarthrit.2020.09.001

     

    Vous souhaitez échanger
    avec nos équipes

    Contactez-nous

    D’autres articles qui pourraient
    vous intéresser

    Cost utility modeling of early vs late total knee replacement in osteoarthritis patients.
    Rhumatologie

    Cost utility modeling of early vs late total knee replacement in osteoarthritis patients.

    Predictive value of tender joints compared to synovitis for structural damage in rheumatoid arthritis
    Rhumatologie

    Predictive value of tender joints compared to synovitis for structural damage in rheumatoid arthritis

    Etude transversale internationale de la prévalence des comorbidités dans la polyarthrite rhumatoïde (PR) et évaluation de leur suivi (COMORA Study : COMOrbidities in Rheumatoid Arthritis)
    Rhumatologie

    Etude transversale internationale de la prévalence des comorbidités dans la polyarthrite rhumatoïde (PR) et évaluation de leur suivi (COMORA Study : COMOrbidities in Rheumatoid Arthritis)